miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors.

Florian Huemer; Michael Leisch; Roland Geisberger; Nadja Zaborsky; Richard Greil

doi:10.3390/ph14020089

miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors.

Florian Huemer (First author), Michael Leisch (Co-author), Roland Geisberger (Co-author), Nadja Zaborsky (Co-author), Richard Greil^* (Last author)

^*Corresponding author for this work

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Review article › peer-review

11 Citations (Web of Science)

Original language	English
Journal	Pharmaceuticals (Basel, Switzerland)
Volume	14
Issue number	2
DOIs	https://doi.org/10.3390/ph14020089
Publication status	Published - 2021

Keywords

SQUAMOUS-CELL CARCINOMA
TUMOR-SUPPRESSOR MICRORNAS
LUNG-CANCER
OPEN-LABEL
SOLID TUMORS
DOUBLE-BLIND
NIVOLUMAB
PEMBROLIZUMAB
CHEMOTHERAPY
IPILIMUMAB

Access to Document

10.3390/ph14020089

Cite this

@article{d656f197fe774ef99ad157d98f95d588,

title = "miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors.",

keywords = "SQUAMOUS-CELL CARCINOMA, TUMOR-SUPPRESSOR MICRORNAS, LUNG-CANCER, OPEN-LABEL, SOLID TUMORS, DOUBLE-BLIND, NIVOLUMAB, PEMBROLIZUMAB, CHEMOTHERAPY, IPILIMUMAB",

author = "Florian Huemer and Michael Leisch and Roland Geisberger and Nadja Zaborsky and Richard Greil",

note = "all: Paracelsus Med Univ, Oncol Ctr, Dept Internal Med Haematol Med Oncol Haemostaseol, A-5020 Salzburg, Austria; ",

year = "2021",

doi = "10.3390/ph14020089",

language = "English",

volume = "14",

journal = "Pharmaceuticals (Basel, Switzerland)",

issn = "1424-8247",

number = "2",

}

TY - JOUR

T1 - miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors.

AU - Huemer, Florian

AU - Leisch, Michael

AU - Geisberger, Roland

AU - Zaborsky, Nadja

AU - Greil, Richard

N1 - all: Paracelsus Med Univ, Oncol Ctr, Dept Internal Med Haematol Med Oncol Haemostaseol, A-5020 Salzburg, Austria;

PY - 2021

Y1 - 2021

KW - SQUAMOUS-CELL CARCINOMA

KW - TUMOR-SUPPRESSOR MICRORNAS

KW - LUNG-CANCER

KW - OPEN-LABEL

KW - SOLID TUMORS

KW - DOUBLE-BLIND

KW - NIVOLUMAB

KW - PEMBROLIZUMAB

KW - CHEMOTHERAPY

KW - IPILIMUMAB

U2 - 10.3390/ph14020089

DO - 10.3390/ph14020089

M3 - Review article

C2 - 33530393

SN - 1424-8247

VL - 14

JO - Pharmaceuticals (Basel, Switzerland)

JF - Pharmaceuticals (Basel, Switzerland)

IS - 2

ER -